Zobrazeno 1 - 10
of 30
pro vyhledávání: '"J J, Ortega Aramburu"'
Autor:
P, Bastida Vilá, C, Palacio García, M, Solsona Riera, J J, Ortega Aramburu, J, Sánchez de Toledo Codina
Publikováno v:
Anales de pediatria (Barcelona, Spain : 2003). 63(5)
Early response to induction treatment is one of the most important prognostic factors in children with acute lymphoblastic leukemia (ALL). Cytological remission is currently achieved in 95-98 % of these patients, although a significant proportion wil
Publikováno v:
Anales de pediatria (Barcelona, Spain : 2003). 61(6)
Transient neonatal leukemia or transient neonatal myeloproliferative disorder is commonly associated with Down syndrome. It usually resolves spontaneously in 4-5 months. However, 25 % of patients will subsequently develop acute megakaryoblastic leuke
Autor:
A, Díaz Conradi, C, Díaz de Heredia, J, Tusell Puigbert, S, Quintana Riera, L, Tobeña Boada, J J, Ortega Aramburu
Publikováno v:
Anales de pediatria (Barcelona, Spain : 2003). 59(1)
Immune thrombocytopenic purpura (ITP) is characterized by a drop in platelet count usually accompanied by hemorrhagic diathesis. In chronic forms the platelet count remains low for six months after diagnosis and in recurrent forms the drop in platele
Autor:
J M, Tusell Puigbert, C, Aulesa Martínez, M, Aguirre Canyadell, I, Nicolau Fusté, P, Valentín Valentín, J J, Ortega Aramburu
Publikováno v:
Anales espanoles de pediatria. 53(1)
It has been suggested that the cause of Perthes disease may be intravascular thrombosis induced by a potential congenital hemostatic disorder leading to conditions of thrombophilia or hyperfibrinolysis.Complete study of hemostasis with coagulation an
Autor:
A, Muñoz Villa, J J, Ortega Aramburu, E, Bureo Dacal, I, Badell Serra, L, Madero López, T, Olive Oliveras, J, Cubells Riero, M S, Maldonado Regalado, M, Ramírez Orellana
Publikováno v:
Anales espanoles de pediatria. 50(1)
The objective of this study was to evaluate retrospectively the efficacy of allogeneic BMT in the treatment of childhood severe acquired aplastic anemia (SAAA).Twenty-seven children aged 2 to 16 years (median 11 years) received a BMT from an HLA iden
Autor:
F, Castillo Salinas, C, Díaz de Heredia Rubio, S, Salcedo Abizanda, A, Ferrer Comalat, P, Bastida Vila, J J, Ortega Aramburu, G, Peguero Monforte
Publikováno v:
Anales espanoles de pediatria. 49(6)
To assess the therapeutic effect of G-CSF in newborns with neutropenia.Newborn with evidence of both peripheral neutropenia and decreased granulocytic precursors in tibial bone marrow aspirate were included in the study. G-CSF was perfused intravenou
Autor:
C, Rodríguez Galindo, J J, Ortega Aramburu, J L, Alonso, M, Albisu, J, Casaldáliga, C, Díaz de Heredia, T, Olivé, P, Bastida
Publikováno v:
Medicina clinica. 102(19)
The current treatment of thalassaemia maior (TM) is based on a hypertransfusion regimen, with deferoxamine (DFO) chelation therapy to minimize the consequences of iron overload. To evaluate the long-term efficacy of chelation therapy, a group of 9 pa
Publikováno v:
Anales espanoles de pediatria. 35(3)
Changes in treatment of ANLL in children over 23 years (1968-90) and advances made in the last ten years in a pediatric hematological unit are reported herein. Of 124 patients under 15 years of age, 18 of whom were infants, 118 were evaluable. Of the
Publikováno v:
Anales espanoles de pediatria. 33(4)
Bone marrow transplant has proved to be an effective treatment in some hereditary metabolic diseases and, especially, in mucopolysdaccharidosis (MPS). A 9-year-old girl, of consanguineous parents, with MPS Type I, Hurler-Scheie syndrome, received a B
Publikováno v:
Anales espanoles de pediatria. 33(2)